Geldanamycin, a benzoquinone ansamycin, has been found to revert tyrosine kinase-induced oncogenic transformation. In the same study it was reported that Geldanamycin was able to bind elements of Hsp90 (heat shock protein 90) clients, such as HIF-1α (Hypoxia-inducible factor-1-α), and inhibit them. Geldanamycin binds in a specific and stable manner and as a result inhibits new protein maturation. Geldanamycin binds with high affinity into the ATP binding pocket of Hsp90. These heat shock proteins might positively impact cell proliferation by being a chaperone required for the assembly and activation of telomerase in cells. By binding them, Geldanamycin is thought to reduce new protein maturation and their downstream transcriptional activity. Geldanamycin has also displayed a capacity to bind to the endoplasmic reticulum homologue of the heat-shock protein, GP-96 and thus interferes with the cellular stress response. In addition, Geldanamycin has been reported as a potent inhibitor of the nuclear hormone receptor family. Other research has demonstrated Geldanamycin to be a protective agent against α-synuclein toxicity to dopaminergic neurons in Drosophila. Geldanamycin is an inhibitor of c-Src.
1. Whitesell, L., et al., 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America. 91(18): 8324-8. PMID: 8078881
2. Mabjeesh, Nicola J., et al., 2002. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer research. 62(9): 2478-82. PMID: 11980636
3. Koga, Fumitaka., et al., 2007. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell cycle (Georgetown, Tex.). 6(11): 1393-402. PMID: 17525527
4. Li, Yan-Ping., et al., 2010. Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities. Antiviral chemistry & chemotherapy. 20(6): 259-68. PMID: 20710066
See how others have used Geldanamycin. Click on the entry to view the PubMed entry .
PMID: # 31540279 2019. Cancers (Basel). 11:
PMID: # 31121848 Gilardini Montani, MS.|Cecere, N.|Granato, M.|Romeo, MA.|Falcinelli, L.|Ciciarelli, U.|D'Orazi, G.|Faggioni, A.|Cirone, M.| et al. 2019. Cancers (Basel). 11:
PMID: # 28360195 Giráldez, S. et al. 2017. FASEB J. 31: 2925-2936.
PMID: # 26791531 Wang, HH. et al. 2016. Histochemistry and cell biology. 145: 647-57.
PMID: # 25941378 Malinovska, L.|Palm, S.|Gibson, K.|Verbavatz, JM.|Alberti, S.| et al. 2015. Proc. Natl. Acad. Sci. U.S.A. 112: E2620-9.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.